Efficacy and safety of elobixibat in hemodialysis patients with chronic constipation -Retrospective observation research
Not Applicable
- Conditions
- Chronic constipation complicated with chronic renal disease
- Registration Number
- JPRN-UMIN000037285
- Lead Sponsor
- Hyakutake Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 23
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who had a history of hypersensitivity of elobixibat 2. Patients who are confirmed or suspected intestinal obstruction due to tumor, hernia etc 3. Patients who are suspected constipation due to organic disease 4. Patients whose physicians judged that administration of elobixibat was inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of frequency of spontaneous bowel movement between baseline and week 12 of administration
- Secondary Outcome Measures
Name Time Method Changes in the frequency of spontaneous bowel movements during 12 weeks Changes in the Bristol Stool Form Scales during 12 weeks and comparison between baseline to at weeks 12 of administration Comparison in the patient satisfaction (VAS) between baseline and at weeks 12 of administration Comparison in the Constipation Scoring System between baseline and at weeks 12 of administration Changes in the body weight gain of interdialytic period per week during 12 weeks and comparison between baseline and at weeks 12 of administration Changes in the concentration of serum phosphorus, potassium, sodium, chloride, calcium, albumin during 12 weeks and comparison between baseline and at weeks 12 of administration Comparison in the concentration of serum LDL-cholesterol between baseline and at weeks 12 of administration